Lordrick Alinaitwe
ID:
|
Transmission and Occurrence of Leptospira infection among humans and livestock in Uganda
REFNo: HS1563ES
To determine the extent, risk factors and potential pathways for Leptospira transmission and infection among potential reservoir animals and human populations in Uganda.,To describe potential pathways and drivers for Leptospira transmission at the animal-human-environmental interface in Uganda, based on statistical modelling,To identify Leptospira species and serogroups that circulate in humans, livestock, and environmental sources in Uganda.,To determine Leptospira seroprevalence and infection among slaughter ruminants and swine in Uganda,To determine Leptospira seroprevalence and associated risk factors among slaughter workers in Uganda,
|
Uganda |
2021-08-25 |
2024-08-25 |
Medical and Health Sciences |
Non-Clinical Trial |
Degree Award |
|
Mary Goretti Nakabugo Goretti
ID: UNCST-2021-R013051
|
Are our Children Learning? Uwezo Basic Assessment of Literacy and Numeracy.
REFNo: SS959ES
Uwezo Uganda intends to undertake the 2021 assessment of basic learning outcomes in literacy and numeracy in order that:
i) Independent evidence on learning levels in literacy and numeracy of children aged 4-16 in Uganda is generated.
ii) The data generated from conducting the learning assessments increases knowledge, awareness and understanding of policy actors, practitioners and the public of children’s learning outcomes and their distribution and that the evidence is used to improve resource allocation and the delivery of education.
|
Uganda |
2021-08-25 |
2024-08-25 |
Social Science and Humanities |
Non-Clinical Trial |
Non-degree Award |
|
Patrick Vudriko
ID:
|
Innovations to Address Rampant Vaccine Failures, Shortages and Low Uptake for Sustainable Livestock Disease Control and Productivity in Uganda
REFNo: A136ES
The Proposal is designed to address selected immunizable diseases that affect health and productivity of poultry, small ruminant and cattle in Uganda. The study objectives include;
1. To assess the current animal vaccine supply chain and identify actors, distribution channels, use and constraints that affects animal vaccine utilization in Uganda.
2. To evaluate the level of protective Gumboro & IB virus disease antibodies among vaccinated chicken flocks in commercial farms.
3. To assess the sero-conversion of FMD vaccine and strengthen vaccination efficacy monitoring lab service at Research Center for Tropical Diseases and Vector Control (RTC) Laboratory at COVAB.
4. To assess the current PPR vaccination regimen and the clinical performance of combined PPR- SGP virus vaccine under field situations in small ruminants and develop a vaccination technical framework for effective control of the two diseases in Uganda.
|
Uganda |
2021-08-25 |
2024-08-25 |
Agricultural Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Mike Kyewalyanga
ID: UNCST-2021-R013531
|
Factors associated with virological non-suppression among HIV- Positive children under 5 years on antiretroviral therapy in Mbarara Regional Referral Hospital
REFNo: HS1584ES
1.To determine the proportion of virological non-suppression among HIV positive children under 5 years who have been on ART for at least 6 months, in the ISS clinic of Mbarara Regional Referral Hospital.
2.To determine the factors associated with virological non-suppression among HIV positive children under 5 years who are receiving ART from ISS clinic of Mbarara Regional Referral Hospital.
3.To determine the perceptions of health-care providers and parents/guardians on factors associated with virological non-suppression among HIV positive children under 5 years who are receiving ART from ISS clinic of Mbarara Regional Referral Hospital.
|
Uganda |
2021-08-25 |
2024-08-25 |
Medical and Health Sciences |
Non-Clinical Trial |
Degree Award |
|
Luz Azlor del Valle
ID:
|
GAFSP Private Sector Window Uganda Impact Evaluation - Baseline
REFNo: SS943ES
The primary research question is – what is the impacts of an expansion in the fertiliser business on smallholder farmers. The purpose of the evaluation is to account for the interventions and support provided and to derive lessons and recommendations to improve future impact. To meet these objectives the eventual impact evaluation will attempt to answer the following evaluation questions:
1. How does the project affect yields?
2. How does the project affect household income and poverty status of farmers?
3. What is the project’s impact on food security and nutrition?
4. What is the project’s impact on women’s status and empowerment?
|
Spain |
2021-08-25 |
2024-08-25 |
Social Science and Humanities |
Non-Clinical Trial |
Non-degree Award |
|
Jayne Ellis
ID: UNCST-2021-R013987
|
“Integrated management of cryptococcal and opportunistic infections to improve outcomes in advanced HIV disease (IMPROVE study)â€
REFNo: HS1607ES
1) To generate evidence on the safety (adverse events) and feasibility (adherence and tolerability) of 1HP (one month of isoniazid and rifapentine) for TB preventative therapy (TPT) amongst adults with HIV-associated cryptococcal meningitis.
2) To generate preliminary data on potential secondary benefits (reduced loss to follow-up, reduced active TB disease, reduced mortality due to TB) of early (inpatient initiation) 1HP TPT as compared to standard (outpatient initiation) 1HP TPT amongst adults with HIV-associated cryptococcal meningitis.
|
UK |
2021-08-25 |
2024-08-25 |
Medical and Health Sciences |
Clinical Trial |
Degree Award |
|
Moses Joloba Lutaakome
ID: UNCST-2022-R011558
|
Bacterial and Host Determinants in TB Transmission: Immune Phenotypes Associated with Exposure to High and Low Transmission Strains of MTB - Uganda
REFNo: HS1498ES
The goal of this study is to identify the bacterial and host factors that promote transmission of tuberculosis (TB), a necessary first step towards developing drugs and vaccines that prevent the inter-person spread of Mycobacterium tuberculosis (Mtb). This study has five specific aims:
Aim 1: Determine the extent to which household transmission is responsible for co-prevalent and incident TB cases caused by Mtb strains that are genetically distinct from those isolated from the index cases within the same household.
Aim 2: Investigate the in vitro immune phenotype of transmitted versus not-transmitted Mtb strains in households stratifying for HIV status.
Aim 3: Characterize the innate macrophage response to high and low transmission strains and the T-cell response in persons with known household exposure to high and low transmission isolates and the impact of HIV infection.
Aim 4: Identify the component of Mtb genes that aid in bacterial survival in aerosols.
Aim 5: Investigate the bacterial factors underlying divergence in the host response to high and low transmission isolates.
|
Uganda |
2021-08-24 |
2024-08-24 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Peter Elyanu James
ID: UNCST-2021-R013210
|
CoVPN 3008- UBUNTU Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern. Version 1.0, dated 16 May 2021. DAIDS Document ID # 38838.
REFNo: HS1642ES
Primary Objectives
The primary objectives of this study are to determine the following:
1. To assess vaccine efficacy (VE) of COVID-19 mRNA vaccine to prevent virologically-confirmed symptomatic COVID-19 starting 14 days after dose 2 in adults who are at risk of severe COVID-19
2. To assess vaccine efficacy (VE) of COVID-19 mRNA vaccine to prevent severe COVID-19 starting 14 days after dose 2 in adults who are at risk for severe COVID-19
3. To assess safety and tolerability of COVID-19 mRNA vaccine in adults who are at risk of severe COVID-19
Secondary Objectives
The secondary objectives of this study are to evaluate the following:
1. Durability of VE of COVID-19 mRNA vaccine against COVID-19 and against severe COVID-19 through the final study visit (Month 12 post-dose 1) in volunteers with no previous COVID-19
2. VE of COVID-19 mRNA vaccine against COVID-19 and against severe COVID-19 by neutralization phenotype and Spike sequence features of acquired SARS-CoV-2 viruses (sieve analysis), including VE against the B.1.351/501Y.V2 variant and VE against all other variants combined in volunteers with no previous COVID-19
3. VE of COVID-19 mRNA vaccine against SARS-CoV-2 infection defined by nucleocapsid protein seroconversion regardless of symptomology in volunteers with no previous COVID-19
4. VE of COVID-19 mRNA vaccine against asymptomatic SARS-CoV-2 infection defined by nucleocapsid protein seroconversion without prior occurrence of the symptomatic COVID-19 primary endpoint in volunteers with no previous COVID-19
5. Post -vaccination immune response markers as correlates of risk of COVID-19 and as correlates protection against COVID-19
6. VE of COVID-19 mRNA vaccine against COVID-19 and severe COVID-19 in all participants regardless of baseline SARS-CoV-2 status
Exploratory Objectives
The exploratory objectives of this study are to evaluate the following:
1. VE of COVID-19 mRNA vaccine against COVID-19 and severe COVID-19 by baseline HIV infection status in volunteers with no previous COVID-19 and in all volunteers regardless of previous COVID-19 status
2. VE of COVID-19 mRNA vaccine against COVID-19 and against severe COVID-19 by neutralization phenotype and Spike sequence features of acquired SARS-CoV-2 viruses (sieve analysis), including VE against the B.1.351/501Y.V2 variant and VE against all other variants combined in volunteers with no previous COVID-19 and in all volunteers regardless previous COVID-19 status
3. VE of COVID-19 mRNA vaccine against COVID-19 and severe COVID-19 in volunteers with previous COVID-19
4. Relative rate of COVID-19 and severe COVID-19 in placebo recipients with previous COVID-19 compared to vaccine recipients with no previous COVID-19
5. Assess T-cell responses in placebo recipients who develop COVID-19 compared to vaccine recipients who develop symptomatic COVID-19
6. Assess incidence of adverse birth outcomes among pregnant persons enrolled in the trial
|
Uganda |
2021-08-24 |
2024-08-24 |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Perez Mujuni Perez Mbiire Batwine
ID:
|
Teachers' welfare, human capital and performance of Government aided primary school in Isingiro District
REFNo: SS964ES
i. To establish the relationship between teachers’ welfare and performance of government aided primary schools in Isingiro District.
ii. To establish the relationship between human capital and performance of government aided primary schools in Isingiro District.
iii. To find out the effect of combining teachers’ welfare and human capital on the performance of government aided primary schools in Isingiro District.
iv. To find out whether monitoring systems mediates teachers’ welfare and the performance of government aided primary schools in Isingiro District.
v. To find out whether monitoring systems mediates human capital and the performance of government aided primary schools in Isingiro District.
|
Uganda |
2021-08-23 |
2024-08-23 |
Social Science and Humanities |
Non-Clinical Trial |
Degree Award |
|
Hasifah Namatovu Kasujja
ID:
|
eHealth Adoption in Uganda. What is the status? eHAU
REFNo: SS945ES
1. To inventory existing eHealth interventions in Uganda to ascertain maturity, failure and successes
2. To study the barriers and facilitators of eHealth adoption in Uganda
3. To develop a framework for successful eHealth adoption
4. To evaluate the framework for utility
|
Uganda |
2021-08-23 |
2024-08-23 |
Social Science and Humanities |
Non-Clinical Trial |
Non-degree Award |
|
| View |
|
Sort By: |
|
|
|
| |
|